Home>Topics>Stocks>Roche Holding AG ADR

Roche Holding AG ADR RHHBY

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Pacific Bio earns $10M milestone from Roche

      Headlines

      Thu, 28 Aug 2014

      Pacific Biosciences of California (NASDAQ: PACB ) achieves a development milestone under its agreement with Roche ( OTCQX: RHHBY ) triggering a $10M milestone payment. The companies signed a Development, Commercialization and License Agreement on September

    2. GenMark Diagnostics Hoping To Make Its Mark In Clinical MDx

      Headlines

      Wed, 27 Aug 2014

      diagnostics is still a relatively new opportunity in the clinical diagnostics space - about $4 billion/year if Roche 's (OTCQX: RHHBY ) estimates of its market share are accurate. It remains a good growth opportunity, though, as molecular diagnostic technologies

    3. With An Iffy Non-Oncology Pipeline, Roche Pays Up For InterMune

      Headlines

      Tue, 26 Aug 2014

      By Stephen Simpson, CFA : Roche ( OTCQX: RHHBY ) does a lot of things well. It is one of the largest players in oncology and markets three of the top ten best-selling drugs

    4. Why I Bought Into Monday's Move In Regeneron

      Headlines

      Tue, 26 Aug 2014

      By DoctoRx : Background : On August 8, I did my first and only article on Regeneron (NASDAQ: REGN ), titled The Case That Regeneron May Be Significantly Undervalued . This company has a rapidly-growing franchise for retinal problems and a large partnership with the French major pharma company ...

    5. Solid Management And Robust Balance Sheet Point To Large Upside For Prothena

      Headlines

      Mon, 25 Aug 2014

      By EnhydrisPECorp : Prothena Corporation plc (NASDAQ: PRTA ) is a little-known Irish biopharma developing novel treatments for a host of rogue protein-based diseases that reap absolute havoc within our bodies. Some examples of these killers include Alzheimers, Parkinsons, and Amyloid Light-chain ...

    6. Roche deal stokes biotech sector

      Headlines

      Mon, 25 Aug 2014

      Roche's ( OTCQX: RHHBY +0.6% ) $8.3B acquisition of InterMune ( ITMN +35.7% ) fuels an inflow of money into the biotech sector today. The iShares NASDAQ Biotech Index ETF ( IBB +2.2% ) is up on average volume. ETFs: BIB , BIS Post your comment!

    7. FDA clears label expansion for Iroko Pharma pain med

      Headlines

      Mon, 25 Aug 2014

      adults in October 2013. Related tickers: ( PFE +0.1% ) ( MRK +0.9% ) ( OTCPK:BAYZF ) ( OTCPK:BAYRY +1.2% ) ( OTCQX: RHHBY +0.6% ) ( TEVA -0.5% ) ( MYL +0.8% ) ( PRGO -0.1% ) ( GSK +0.8% ) Post your comment!

    8. Chugai comes in second to InterMune

      Headlines

      Mon, 25 Aug 2014

      Shares of Chugai Pharmaceutical Co. dropped over 9% on the Tokyo exchange after Roche ( OTCQX: RHHBY ) decided to spend its money on InterMune (NASDAQ: ITMN ) instead. According to Chugai, "it is in no way in the process of

    9. Roche to buy InterMune for $8.3B in cash

      Headlines

      Sun, 24 Aug 2014

      Roche ( OTCQX: RHHBY , OTCPK:RHHBF ) will pay $74/share for InterMune (NASDAQ: ITMN ), a 38% premium to its Friday close and 63% higher than

    10. Risk And Reward Seem Pretty Balanced At Seattle Genetics

      Headlines

      Tue, 19 Aug 2014

      By Stephen Simpson, CFA : Oncology biotech Seattle Genetics (NASDAQ: SGEN ) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of ...

    « Prev12345Next »
    Content Partners